A novel JAK inhibitor JTE‐052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Janus kinases (JAK s) are required for several inflammatory cytokine signalling pathways and are implicated in the pathogenesis of chronic dermatitis, including atopic dermatitis and psoriasis.JAK inhibitors are therefore promising therapeutic candidates for chronic dermatitis. In this study, we evaluated the effects of the novel JAK inhibitor JTE‐052 on inflammatory responses associated with chronic dermatitis, and compared its profile with those of conventional therapeutic agents in rodent models of chronic dermatitis.JTE‐052 inhibited the Th1‐, Th2‐ and Th17‐type inflammatory responses of human T cells and mast cells in vitro. Oral administration of JTE‐052 inhibited skin inflammation in hapten‐induced chronic dermatitis in mice, associated with reduced levels of inflammatory cytokines in the skin and immunoglobulin (Ig) E in serum. In contrast, although ciclosporin partly inhibited skin inflammation, it did not reduce interleukin (IL)‐4 production in skin, and enhanced IgE production in serum. Oral administration of JTE‐052 also inhibited skin inflammation in mouse models of atopic dermatitis and psoriasis induced by a mite extract, thymic stromal lymphopoietin or IL‐23. The maximal efficacy of JTE‐052 in these dermatitis models was superior to the conventional therapeutic agents, ciclosporin and methotrexate. Topical application of JTE‐052 ointment ameliorated hapten‐induced chronic dermatitis in rats more effectively than tacrolimus ointment. Furthermore,JTE‐052 ointment did not cause the thinning of normal skin associated with topical corticosteroids. These results indicate that JTE‐052 is a promising candidate as an anti‐inflammatory drug for various types of chronic dermatitis, with a distinctly different profile from conventional therapy following either oral or topical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Amano, W., Nakajima, S., Kunugi, H., Numata, Y., Kitoh, A., Egawa, G., Dainichi, T., Honda, T., Otsuka, A., Kimoto, Y., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.03.051 · Cited by 259
Self-citationTanimoto, A., Ogawa, Y., Oki, C., Kimoto, Y., Nozawa, K., Amano, W., Noji, S., Shiozaki, M., Matsuo, A., Shinozaki, Y., et al. (2015) · Inflammation Research · doi:10.1007/s00011-014-0782-9 · Cited by 111
Self-citationEpidermal barrier in hereditary ichthyoses, atopic dermatitis, and psoriasis
Schmuth, M., Blunder, S., Dubrac, S., Gruber, R., & Moosbrugger‐Martinz, V. (2015) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.12827 · Cited by 47
Cited by
JAK inhibitors in the treatment of atopic dermatitis
Chovatiya, R., & Paller, A. S. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.009 · Cited by 398
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kaino, H., & Nagata, T. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.015 · Cited by 242
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01291-2 · Cited by 126
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Murata, R., Kaino, H., & Nagata, T. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15173 · Cited by 105
JAK/STAT inhibitors for the treatment of atopic dermatitis
Rodrigues, M. A., & Torres, T. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1577549 · Cited by 97
Metadata
- Authors
- Tanimoto, A., Shinozaki, Y., Yamamoto, Y., Katsuda, Y., Taniai‐Riya, E., Toyoda, K., Kakimoto, K., Kimoto, Y., Amano, W., Konishi, N., & Hayashi, M.
- Venue
- Experimental Dermatology
- Publisher
- Wiley
- Published
- 2017-07-03
- Volume
- 27
- Issue
- 1
- Pages
- 22-29
- ISSN
- 0906-6705 (ISSN-L)
- 1600-0625
- OpenAlex
- W2607449794
- Cited by
- 60
- References
- 4
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel JAK inhibitor JTE‐052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents. https://app.cochat.ai/papers/10.1111/exd.13370
- The paper
- Tanimoto, A., Shinozaki, Y., Yamamoto, Y., Katsuda, Y., Taniai‐Riya, E., Toyoda, K., Kakimoto, K., Kimoto, Y., Amano, W., Konishi, N., & Hayashi, M. (2018). A novel JAK inhibitor JTE‐052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents. Experimental Dermatology. https://doi.org/10.1111/exd.13370
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.